Fresenius Medical Care to support NHSBT's LDL removal apheresis systems
- NHS Blood and Transplant
- South West
- Call-off from a framework agreement
- 20 January 2026 to 19 January 2028
NHS Blood and Transplant (NHSBT) ordered support for its existing Low Density Lipid (LDL) removal apheresis systems from Fresenius Medical Care.
The systems serve NHSBT's Therapeutic Apheresis Services, which treat children and adults from different clinical specialties. Treatment happens at the patient's hospital bedside or, when clinically suitable, as an outpatient in one of 11 NHSBT units in England and Wales.
The order was placed through a framework agreement. The £337,798 contract covers two years and runs to January 2028.
Contract ends January 2028
- What
- Blood collection, apheresis and component processing
- Supplier
- Fresenius Medical Care
- Value
- £337,798
- How it was bought
- Call-off from a framework agreement
- Dates and next
- Jan 2026 to Jan 2028